eligibility_summary
Adults ≥18 with confirmed HL/CLL or NHL (LBCL, FL, MCL, MZL), measurable disease, R/R after ≥2 lines, prior CD19 CAR‑T relapse/IR or ineligible/refuse, KPS≥70/ECOG 0–1, life ≥12 wks, adequate organs. Exclude bulky disease, active CNS lymphoma, immunodeficiency, severe autoimmune/CNS disease, unresolved ICANS/toxicity, major cardiac disease, HIV/HBV/HCV, active infection or severe allergy, pregnancy, protocol washouts apply.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT05798897 (Phase 1, single-arm). Intervention: MT-601, an autologous cellular immunotherapy consisting of ex vivo–expanded, multi–tumor-associated antigen (TAA)-specific CD4+ and CD8+ T cells (type: adoptive T-cell therapy). Mechanism of action: TCR-mediated recognition of multiple lymphoma TAAs presented by HLA on tumor cells, leading to cytotoxic killing (perforin/granzyme) and helper cytokine support, multi-antigen targeting aims to reduce antigen escape seen with single-target therapies (e.g., CD19 CAR T). Targets: malignant cells in relapsed/refractory non-Hodgkin and Hodgkin lymphomas (e.g., LBCL, FL, MCL, MZL, HL, with potential cohorts for CLL/SLL, CNS lymphoma, CAR T–refractory). Key pathways/cells affected: TCR/HLA antigen presentation, CD8+ cytotoxic T-cell activity, CD4+ helper T-cell activation within the tumor microenvironment. Dose: 200–400 million cells.